FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

42 letters match. Newest first.

  1. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  2. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  3. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  4. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  5. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  6. Owen Biosciences, Inc.

    Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

    High risk
  7. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  8. ABBE Laboratories, Inc.

    FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.

    High risk
  9. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  10. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  11. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  12. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  13. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  14. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  15. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  16. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk
  17. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk
  18. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  19. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  20. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  21. Colgin, Inc.

    FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

    High risk
  22. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  23. Handock Cosmetics Co., Ltd.

    FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.

    High risk
  24. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  25. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  26. Premier Nutra Pharma Inc.

    FDA cited Premier Nutra Pharma, a Carlsbad, California contract maker of nasal spray drugs, for CGMP violations after microbial contamination.

    High risk
  27. Zermat International S.A. de C.V.

    FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.

    High risk
  28. Eco Lips, Inc.

    FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.

    High risk
  29. Cosmetic Science Laboratories LLC

    FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.

    High risk
  30. Formology Lab Inc.

    FDA warned Formology Lab Inc. about manufacturing rule violations for drugs, including untested ingredients and unvalidated sunscreen processes.

    High risk
  31. Frenda Corporation

    FDA found Frenda made OTC alcohol and hand sanitizer under insanitary conditions with industrial chemical cross-contamination risk.

    High risk
  32. Auto-Chlor System LLC

    Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.

    High risk
  33. Kari Gran Inc.

    Kari Gran Inc. released OTC SPF sunscreen drugs without adequate batch testing or stability data.

    High risk
  34. American Cleaning Solutions

    FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.

    High risk
  35. Sanitizer Supply LLC

    FDA warns Sanitizer Supply LLC that its hand sanitizer wipes and sanitizers lacked required potency and microbial testing before release.

    High risk
  36. Verde Cosmetic Labs LLC

    FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.

    High risk
  37. Genlabs Corporation

    FDA warns Genlabs Corporation of Chino, California, that its OTC hand soaps are adulterated and misbranded after finding serious CGMP failures.

    High risk
  38. Colorful Products Corporation

    FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.

    High risk
  39. Specialty Process Labs LLC

    FDA warned Specialty Process Labs about manufacturing quality failures for thyroid USP active ingredient, including unvalidated processes and data control gaps.

    High risk
  40. Agropharma Laboratories, Inc.

    FDA cited Agropharma Laboratories in Salinas, Puerto Rico, for serious manufacturing violations affecting its OTC antiseptics and hand sanitizers.

    High risk
  41. Novel Laboratories, Inc. d.b.a LUPIN

    FDA warned Lupin's Novel Laboratories over manufacturing violations including equipment cross-contamination and unvalidated temazepam capsules.

    High risk
  42. Yuyao YiJia Daily Chemical Co., Ltd.

    Yuyao YiJia, a Chinese OTC drug and hand sanitizer maker, lacked finished-product, component and stability testing and an adequate quality unit.

    High risk